ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener πŸ¦‹ Butterfly 8 Analysts πŸ›οΈ Policy 🎬 Video β˜… Watchlist 🎲 Prediction Markets πŸ“Š RQD Track Record πŸ“… Next Catalysts πŸ›‘οΈ Overlap & Crash X-Ray πŸ“° Live Wire πŸ‹ 13F Whales πŸ›οΈ Congress & CEO Buys πŸ† $100K Arena ⌘ Pro Terminal πŸ“ Methodology & Corrections
Stock Ratings / Health Care / BLLN
CON (68) RDNT (57) VCYT (74) GRAL (54) ⌘ Pro Terminal β†’

BillionToOne Inc. (BLLN) β€” RQD Stock Rating Cockpit

$113.32 -1.32% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $113.32

BillionToOne Inc. (BLLN) earns a Roarable Rating of B- (Buy) with 71/100 RQD Confidence. High-quality cash engine (68% profit margin, 3% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

πŸ“Š Historical Track Record: Scores of 71/100 (B-) historically ranked in the Top 14% of excess returns over the next 90 days (+6.8% avg 90D alpha vs SPY β€’ 68.4% hit rate) β†’
ROARABLE B- β€’ BUY Cap $5.42B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BLLN Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is BLLN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-02, BillionToOne Inc. (NASDAQ: BLLN) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $113.32 (-1.32% 1D, market cap $5.42B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 8/20. Across 1016 tracked Health Care issuers, BLLN ranks #80 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does BLLN compare to CON and RDNT in the Health Care sector?
β–Ό

Within the Health Care sector (Medical Specialities), BLLN carries a Roarable B- (71/100 RQD), trailing P/E of N/A, gross margin of 68.3%, and ROIC of 2.9%. By comparison, CON (Concentra Group Holdings Parent Inc.) holds a C+ grade (68/100 RQD, P/E 31.6x, ROIC 19.7%, cap $5.26B) and RDNT (RadNet Inc.) posts a D+ grade (57/100 RQD, P/E N/A, ROIC 3.5%, cap $5.80B). Among the 5-stock peer group, CON leads on earnings multiple (31.6x) while CON leads on capital efficiency (19.7% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BLLN?
β–Ό

Per BLLN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002070849), BillionToOne Inc. generated $305.1M in revenue (+100.0% YoY), $7.5M in net income, and $15.7M in free cash flow against $632.7M in total assets and $57.2M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $113.32 (+0.00%)🧬 Disciplined Float (+1.08% YoY Shares)βš™οΈ Cash Engine: 14/20 (B-) β€’ 5.2% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record: Scores of 71/100 (B-) historically ranked in the Top 14% of excess returns over the next 90 days (+6.8% avg 90D alpha vs SPY β€’ 68.4% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERBUY β€’ B-
025507510071
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C Β· Rk A-
Cash (14)Whales (16)SEC (18)Macro (15)CEO (8)
Each axis scored 0–20
12M PRICE TARGET CONE+5.9% Base Target
$158 Bull$120 Base$93 Bear
πŸ“¬ FREE BLLN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for BLLN)Realized 20D OHLCV Swing Band: Β±10.7%
Deterministic 5-Pillar Attribution (71/100 Composite)
πŸ” WHY BLLN SCORES 71/100 (B-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (25% of score)

Altman Z-Score 22.24 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 9/9

β–² #2 Bullish Driver: Whale & Options Positioning+16/20 pts (23% of score)

20D Institutional Volume Accumulation (Β±10.7% realized swing band)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution8/20 pts (-12 pt drag)

Disciplined Float (+1.08% YoY Shares) & executive Form 4 sales trim 12 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
63
Grade C+$94.44+9.6% Next Q
Q2 (-2Q)
66
Grade B-$103.50+10.2% Next Q
Q3 (-1Q)
68
Grade B-$114.07-0.7% Next Q
Current
71
Grade B-$113.32+6.8% Hist 90D Ξ±
Trajectory: C+ (63) β†’ B- (71)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

βš”οΈ Adversarial Opposing Case: Why the BLLN Bull Thesis Could Fail

Gideon Ashmere Forensic Desk β†’

Even with a 71/100 (B-) score, BLLN faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (+1.08% YoY Shares) β€” any gross margin slip below 65.8% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($104.57) or 200D SMA ($96.67) invalidates the momentum regime and cuts Target Base ($119.95) toward Bear Floor ($92.92).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BLLNβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œBLLN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 71%NO 29%Trade / Inspect Odds β†’
RSI-14 MOMENTUMBULLISH MOMENTUM
61.230 Oversold Β· 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
22.24>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
9 / 99-Pt Accounting
52-WEEK LASER RANGE58% OF RANGE
L: $62$113.32H: $150
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (68% profit margin), though cash flow growth is moderate rather than explosive right now.

Factor Grade: B-RQD 14 / 20
2. Big Money & Insiders● NEUTRAL
Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: C-RQD 24 / 40
3. Hidden Risks & Market Weather● ALL CLEAR
SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: A-RQD 33 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bullish on BLLN

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (70)

2.9% ROIC with 68.3% gross margin and 0.29% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (90)

Altman-Z 22.24 and Piotroski 9/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
NEUTRAL (65)

24/40 institutional & smart-money positioning score with 15/20 macro alignment.

Bull Case: Why Buyers Like BLLN
  • βœ“Big institutional funds and options desks are actively positioning on the bullish side.
  • βœ“Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (BLLN Tape Review)

  • βœ“Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • βœ“Forensic Red-Light accounting & dilution traps to review on your watchlist
  • βœ“Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
BLLN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +57.13%⚑ TESTING RESISTANCE
2026-11-02O $114.0H $114.8L $113.3C $113.3VOL 583.3K
RES: $117.1SUP: $91.45SMA50: $104.6SMA200: $96.67
$156.0$132.9$109.8$86.74$63.64RES $117.1SUP $91.45$113.32026-05-042026-06-172026-08-042026-09-182026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BLLN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ BLLN Butterfly Map β†’ + Track BLLN β†’
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
48.0%/yr Implied 5Y Growth

vs. +100.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BLLN today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for BLLN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BLLN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BLLN)

Health Care Rank #80 of 1016 βš”οΈ CON vs BLLN Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (BLLN vs. CON, RDNT, VCYT, GRAL)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, BillionToOne Inc. (BLLN) ranks #80 by composite RQD confidence (71/100, grade B-) and #156 by equity capitalization ($5.42B). Within this direct 5-issuer industry benchmark cohort, CON leads on earnings valuation at 31.6x trailing P/E, while CON leads on capital efficiency and profitability with 19.7% ROIC and β€” gross margin. VCYT currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with BLLN at 71/100 (B-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BLLN ACTIVE
BillionToOne Inc.
B- 71/100 β€” 68.3% 2.9% -1.32% $5.42B Benchmark Subject
CON
Concentra Group Holdings Parent Inc.
C+ 68/100 31.6x β€” 19.7% -2.11% $5.26B /con-vs-blln β†’
RDNT
RadNet Inc.
D+ 57/100 β€” β€” 3.5% -0.22% $5.80B /rdnt-vs-blln β†’
VCYT
Veracyte Inc.
B 74/100 63.2x 70.1% 4.6% -4.14% $4.19B /vcyt-vs-blln β†’
GRAL
GRAIL Inc.
D+ 54/100 β€” β€” -18.0% -9.75% $7.10B /gral-vs-blln β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0002070849

In its most recent audited fiscal period (FY2025, filed 2025-12-31), BillionToOne Inc. (BLLN) reported GAAP revenue of $305.1M (+100.0% vs. FY2024 revenue of $152.6M , and +325.4% cumulative change since FY2023) , GAAP net income of $7.5M, operating cash flow of $24.6M, and free cash flow of $15.7M (+133.6% YoY). On the balance sheet, BLLN closed FY2025 with $632.7M in total assets against $57.2M in total debt (Altman Z-Score: 22.24, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $305.1M $7.5M $24.6M $15.7M $632.7M $57.2M
FY2024 (FY) 2024-12-31 $152.6M -$41.6M -$41.4M -$46.8M $302.1M $51.5M
FY2023 (FY) 2023-12-31 $71.7M -$82.7M -$53.7M -$56.9M $2.98B $697.4M

3. BLLN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BLLN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, BillionToOne Inc. (NASDAQ: BLLN) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 71/100 at a spot price of $113.32 (-1.32% 1D, market cap $5.42B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 8/20. Across 1016 tracked Health Care issuers, BLLN ranks #80 in composite RQD confidence.

How does BLLN compare to CON and RDNT in the Health Care sector?

Within the Health Care sector (Medical Specialities), BLLN carries a Roarable B- (71/100 RQD), trailing P/E of N/A, gross margin of 68.3%, and ROIC of 2.9%. By comparison, CON (Concentra Group Holdings Parent Inc.) holds a C+ grade (68/100 RQD, P/E 31.6x, ROIC 19.7%, cap $5.26B) and RDNT (RadNet Inc.) posts a D+ grade (57/100 RQD, P/E N/A, ROIC 3.5%, cap $5.80B). Among the 5-stock peer group, CON leads on earnings multiple (31.6x) while CON leads on capital efficiency (19.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BLLN?

Per BLLN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002070849), BillionToOne Inc. generated $305.1M in revenue (+100.0% YoY), $7.5M in net income, and $15.7M in free cash flow against $632.7M in total assets and $57.2M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BLLN trading relative to its 50-day, 200-day, and 52-week technical levels?

BLLN last traded at $113.32 (-1.32% on volume of 468,452 shares), positioning the stock +8.37% above its 50-day simple moving average ($104.57) and +17.22% above its 200-day simple moving average ($96.67). Across its 52-week range of $61.96 to $150.44, BLLN sits at the 58.0% percentile with a 14-day RSI of 61.2 (BULLISH MOMENTUM) and an implied next-earnings move of Β±10.7% ($101.19 to $125.45).

BLLN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

Should I buy, hold, or sell BLLN stock right now?

BillionToOne Inc. (BLLN) currently earns a Roarable Rating of B- (Buy β€” BUY) with 71/100 RQD Confidence. High-quality cash engine (68% profit margin, 3% return on capital) with steady institutional support.

What is BLLN's 12-month price target and RQD AI Jury consensus?

BLLN's 12-month base price target is $119.95 (range $92.92 to $157.96), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: BLLN RQD Cockpit BLLN 12M Forecast BLLN Earnings & Move BLLN Dividends & DRIP BLLN Insiders & 13F BLLN Whale Options BLLN Profit Sankey BLLN News & Why
ROARABLE RATING BRIEF β€’ RQD 71/100 (B-) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

BLLN β€” BillionToOne Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:20:15Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, BLLN scores 71 out of 100 (letter grade B-, verdict "Roarable Buy β€” Sound Institutional Accumulation"). Across the five pillars: Fundamental Cash Engine 14/20 (ROIC 2.9%; FCF yield 0.29%), Whale 13F Flow 16/20 (institutional accumulation and options positioning), Insider Conviction 8/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 15/20 (Beta 1.02; sector sensitivity), and Forensic Balance Sheet 18/20 (Altman Z 22.24; Piotroski F 9/9; Debt/Equity 0.12).

The strongest pillar is the forensic balance sheet, which indicates low leverage and strong financial-health screens. The weakest pillar is insider conviction, which the rating scores at 8/20 despite the recorded Form 4 activity in the news wire. The cash-engine pillar is moderate: the RQD rating reflects a low ROIC and FCF yield, which tempers the return profile even as revenue has grown. Investor implications: upside drivers appear to be institutional accumulation and balance-sheet strength; valuation tradeoffs are visible in the market data, where EV/EBITDA is 95 and FCF yield is 0.29%, implying the price already embeds substantial expectations relative to current cash generation. This is an educational reading of the rating, not personalized financial advice.

Business

BillionToOne Inc. is a NASDAQ-listed issuer classified under the Health Care sector and the Medical Specialities industry, per the profile section. The source data does not describe its products, customers, or revenue model. The reported margins are a gross margin of 68.3%, an operating margin of 5.3%, and a net margin of 2.4%, per the market data section.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$305.1M$16.0M$7.5MN/A$15.7M$496.0M$57.2M
FY 2024$152.6M$-47.1M$-41.6MN/A$-46.8M$191.5M$51.5M
FY 2023$71.7M$-69.5M$-82.7MN/A$-56.9MN/A$697.4M

Per the SEC financials, revenue grew from $71.7M (FY 2023) to $305.1M (FY 2025), and the company moved from operating losses to a reported operating income of $16.0M in FY 2025. Per the Roarable RQD rating, the Altman Z-Score is 22.24 and the Piotroski F-Score is 9/9, while the market data section reports ROIC of 2.9% and a Debt/Equity of 0.12 within the forensic pillar. Reported FY 2025 cash of $496.0M exceeds reported debt of $57.2M.

Recent Catalysts & News Wire Analysis

  • Seeking Alpha (YELLOW, MARKET WIRE): a report on market action, institutional positioning, and fundamental catalysts, framed around quality and GARP credentials.
  • Investing.com (YELLOW, MARKET WIRE): a report that the CTO sold $2.16M in shares.
  • Stock Titan (YELLOW, MARKET WIRE): a report that a $4.45M sale was followed by a proposal to sell more shares.
  • MarketBeat (RED, RISK WATCH): a report that the stock fell 6.5%.
  • Simply Wall St (YELLOW, MARKET WIRE): a stock forecast and analyst predictions report.
  • MarketBeat (GREEN, CATALYST): a report that the stock rose 3.5%.

The Butterfly Supply-Chain Graph lists no supply-chain links and no proprietary signals.

Open Questions

  • What are BillionToOne's products, customers, and revenue model, given the source data provides only sector and industry labels?
  • What explains the gap between reported FY 2025 net income of $7.5M and the 0.29% FCF yield at a $5.42B market cap?
  • What is the basis for the reported FY 2023 cash figure being N/A while FY 2023 debt is $697.4M, and how did debt decline to $57.2M?
  • What are the trailing and forward earnings per share, which the source data does not provide?
  • What do the insider sales cited in the news wire represent relative to total holdings, and do they reflect scheduled or discretionary activity?

BLLN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for BillionToOne Inc. (BLLN) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to BLLN Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BLLN Bull vs. Bear Conversation Board β€” What's Your Call at $113.32?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BLLN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BLLN:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk πŸ‚ BULLISH 🎯 Target: $135.51 (+18.0%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is BLLN (B- β€’ RQD 71/100) a Buy at $114.84?

Welcome to the BLLN (BillionToOne Inc.) Roar Pit. Current RQD Composite is 71/100 (Roarable Buy β€” Sound Institutional Accumulation) in Medical Specialities. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $89.58 (-22.0%)
Spot @ $114.84

Pump the brakes on BLLN β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on BLLN, but look at what you are paying: current EV/EBITDA multiples with 68.3% gross margins. Unless BillionToOne Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $143.55 (+25.0%)
Spot @ $114.84

BLLN cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on BLLN, the market is fixating on short-term headline noise in Medical Specialities and ignoring the balance sheet and cash flow trajectory. At $114.84 (52-wk range $61.96 - $150.44), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%